Loading stock data…
BCYC
$4.73-0.01 (-0.21%)
Market OpenUpdated 10:49 AM EDT
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BCYC in the Healthcare sector is trading at $4.74. Wall Street consensus targets $12.11 (9 analysts), implying a +155.5% move over the next 12 months. The stock is currently near its 52-week low of $4.24, remaining 27.1% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +155.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$4.73
Potential Downside
0%
Whystock Fair Value$4.73
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$12.11+156.0%
Range$5.00 – $36.00
Fundamentals
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenecti...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.73%
Volume
Today's trading volume
122,083
Recent News
European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday Trading
European equities traded in the US as American depositary receipts were tracking lower late Thursday
European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week
European equities traded in the US as American depositary receipts were trending marginally higher l
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning, gaini
Morgan Stanley Updates Bicycle Therapeutics plc (BCYC) Outlook Amid Pipeline Refocus
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Bicycle Therapeutics plc is one of the best biotech stocks on this list. TheFly reported on April 8 that Morgan Stanley reduced its price target on BCYC to $12 from $13 while maintaining an Equal Weight rating. The firm updated […]
European Equities Traded in the US as American Depositary Receipts Declining in Thursday Trading
European equities traded in the US as American depositary receipts were trending lower late Thursday